Condition: Type II Diabetes · Atherosclerosis · Sponsor: Matthew J. Budoff
A multi-center, randomized, double-blind, placebo-controlled, parallel-group phase IV Study evaluating the effects of tirzepatide on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diagnosis of type II Diabetes (T2DM) and atherosclerosis.
This description comes directly from the study's public registry record.
Sajad Hamal, MS · 13109749336 · shamal@lundquist.org
Ferdinand Flores, BS · 13109749333 · fflores@lundquist.org
Always discuss trial participation with your own doctor first.
| Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute) | Torrance, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05708859